How do price negotiations for pharmaceuticals work in Canada?
2:11
How do price negotiations for pharmaceuticals work in Canada?
Ай бұрын
Why are CADTH conditionally approving therapies?
1:49
Why are CADTH conditionally approving therapies?
Ай бұрын
Patient access challenges for orphan medicines in the Nordic region
1:56
Patient access challenges for orphan medicines in the Nordic region
Ай бұрын
Patient access challenges for rare diseases in the MENA region
2:08
Patient access challenges for rare diseases in the MENA region
2 ай бұрын
What is a partitioned survival model?
3:35
What is a partitioned survival model?
2 ай бұрын
What is a Cox regression model?
4:23
What is a Cox regression model?
2 ай бұрын
Market access and reimbursement in Canada - changes at CADTH
47:44
Market access and reimbursement in Canada - changes at CADTH
2 ай бұрын
What is a discrete event simulation in health economics?
5:47
What is a discrete event simulation in health economics?
2 ай бұрын
What is the vision for primary care provider collaboratives in the NHS?
2:48
What is the vision for primary care provider collaboratives in the NHS?
3 ай бұрын
What is a Markov model? - Health economics model structures
3:32
What is a Markov model? - Health economics model structures
3 ай бұрын
3 challenges your proposal must address for NHS decision-makers
0:54
3 challenges your proposal must address for NHS decision-makers
3 ай бұрын
Rare Disease market access in the MENA and Nordic regions
59:11
Rare Disease market access in the MENA and Nordic regions
3 ай бұрын
What is a decision tree and how is it used in health economics?
4:21
What is a decision tree and how is it used in health economics?
3 ай бұрын
Does your medical device or diagnostic empower patients?
1:40
Does your medical device or diagnostic empower patients?
3 ай бұрын
Optimising NHS funding decisions: focusing on outcomes and ROI
3:26
Optimising NHS funding decisions: focusing on outcomes and ROI
3 ай бұрын
Opportunities to support secondary care in the NHS
1:13
Opportunities to support secondary care in the NHS
3 ай бұрын
Introducing Mtech Access - Leaders in Global Pharma and Medtech Commercialisation
4:44
Introducing Mtech Access - Leaders in Global Pharma and Medtech Commercialisation
4 ай бұрын
Health economic evaluation for HTA in different markets
2:19
Health economic evaluation for HTA in different markets
4 ай бұрын
How does funding flow in NHSE Regions?
1:00:16
How does funding flow in NHSE Regions?
4 ай бұрын
NHS policy for 2024/25: strategy and engagement in a world of uncertainty
1:02:07
NHS policy for 2024/25: strategy and engagement in a world of uncertainty
4 ай бұрын
Get payer input and feedback on your evidence strategy early
1:47
Get payer input and feedback on your evidence strategy early
5 ай бұрын
De-mystifying health economic model classifications and structures
1:00:29
De-mystifying health economic model classifications and structures
5 ай бұрын
Is it worth investing time to launch in NHS Wales?
2:04
Is it worth investing time to launch in NHS Wales?
5 ай бұрын
How does specialised commissioning work in Wales?
1:52
How does specialised commissioning work in Wales?
5 ай бұрын
6 key early decisions when launching new Pharma and Medtech products
4:06
6 key early decisions when launching new Pharma and Medtech products
5 ай бұрын
What would the NHS in Wales want to see from an industry partner?
1:41
What would the NHS in Wales want to see from an industry partner?
5 ай бұрын
Evidence strategy for Medical Technologies and Diagnostics
53:25
Evidence strategy for Medical Technologies and Diagnostics
5 ай бұрын
What is changing for Pharma and Medtech industries in the US?
2:09
What is changing for Pharma and Medtech industries in the US?
5 ай бұрын
How should Pharma respond to the changes to NHS specialised services?
3:13
How should Pharma respond to the changes to NHS specialised services?
5 ай бұрын
Пікірлер